SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-004665
Filing Date
2019-05-09
Accepted
2019-05-09 16:02:28
Documents
61
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20190331x10q.htm 10-Q 1091398
2 EX-31.1 gemp-20190331ex311ecbea3.htm EX-31.1 17913
3 EX-32.1 gemp-20190331ex321346ddb.htm EX-32.1 12136
  Complete submission text file 0001558370-19-004665.txt   3906820

Data Files

Seq Description Document Type Size
4 EX-101.INS gemp-20190331.xml EX-101.INS 624498
5 EX-101.SCH gemp-20190331.xsd EX-101.SCH 36908
6 EX-101.CAL gemp-20190331_cal.xml EX-101.CAL 28029
7 EX-101.DEF gemp-20190331_def.xml EX-101.DEF 109609
8 EX-101.LAB gemp-20190331_lab.xml EX-101.LAB 331014
9 EX-101.PRE gemp-20190331_pre.xml EX-101.PRE 244648
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 19810394
SIC: 2834 Pharmaceutical Preparations